The stock is now trading at a price
before it picked up both analysts, caris and fortis
The great 4 month data on macular degeneration was announced.
The good,but not great,lomucin data was announced. It now has value.
It doesn't make any sense, and don't try to make any sense out of it.
It didn't make any sense when I started buying this at under a dollar in august 2002. I tried to figure out why I was buying it while the funds were selling it. What did they know that I didn't. The answer was NOTHING.
I was right and they were wrong, and I am right now. The squalamine deal is worth multiples of the Eyetech deal and Regeneron deal and the best part is Roy knows it.
Why be concerned about the trial being done in Mexico. Regeneron did their deal with Aventis and they didn't even have any human data.
Got it!
